W. Rackoff

发表

Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study.

David A. Williams, M. Freedman, B. Alter, 1996 .

leukemia and other hematologic malignancies Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid

R. Kurzrock, G. Garcia-Manero, M. Talpaz, 2013 .

Neurologic events after partial exchange transfusion for priapism in sickle cell disease.

J. Scott, A. Cohen, W. Rackoff, 1992, The Journal of pediatrics.

A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.

D. Henry, T. Cooley, Steven Sun, 2007, The oncologist.

Chlamydia pneumoniae and Acute Chest Syndrome in Patients With Sickle Cell Disease

L. Benjamin, C. Pegelow, E. Vichinsky, 2003, Journal of pediatric hematology/oncology.

Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.

R. Coleman, T. Herzog, J. Barter, 2007, The oncologist.

A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy.

P. Hinds, M. Hockenberry, B. Razzouk, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy.

P. Hinds, J. Feusner, M. Hockenberry, 2005, The journal of supportive oncology.

High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.

P. Breitfeld, S. Kreissman, W. Rackoff, 1997, Journal of pediatric hematology/oncology.

Predicting the risk of bacteremia in childen with fever and neutropenia.

R. Gonin, S. Kreissman, W. Rackoff, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children.

V. Stallings, R. Hirschl, L. Bell, 1995, The Journal of pediatrics.

Gas embolism after ingestion of hydrogen peroxide.

W. Rackoff, D. A. Merton, 1990, Pediatrics.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2022 .

Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone.

C. Manno, W. Rackoff, 1994, The American journal of pediatric hematology/oncology.

A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds

J. DiMasi, K. Getz, R. Kondru, 2015, Clinical pharmacology and therapeutics.

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

Steven Sun, M. Tonda, A. Gordon, 2004, Gynecologic oncology.

Early Changes in CA 125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients

R. Coleman, J. Barter, Steven Sun, 2006 .

Ovarian Cancer Patients Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Early Changes in CA 125 After Treatment with Pegylated Liposomal

R. Coleman, J. Barter, Steven Sun, 2006 .

Central venous catheter use and the risk of infection in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group.

H. Sather, B. Lange, R. Hutchinson, 1999, Journal of pediatric hematology/oncology.

Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer

F. Saad, B. Hadaschik, E. Small, 2018, The New England journal of medicine.

SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

F. Saad, B. Hadaschik, E. Small, 2018 .

Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).

F. Saad, B. Hadaschik, E. Small, 2019, Journal of Clinical Oncology.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

P. Sonneveld, A. Nagler, R. Hájek, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

Pierre Fenaux, R. Stone, P. Fenaux, 2007, Blood.

Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study.

D. Williams, M. Freedman, B. Alter, 1996, Blood.

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.

P. Hinds, J. Feusner, M. Hockenberry, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.

N. Heerema, H. Sather, B. Lange, 2002, Blood.

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II

Liang Xiu, N. Bogdanova, J. Sparano, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leto-meningeal melanosis

W. Rackoff, L. Meister, B. Arendash-Durand, 1991 .

Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease.

J. Silber, T. Asakura, W. Rackoff, 1993, Blood.

Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

David C. Atkins, Bob Löwenberg, David Atkins, 2007, Clinical Cancer Research.

Phosphorylation of the hepatic EGF receptor with cAMP-dependent protein kinase

H. Earp, R. A. Rubin, W. Rackoff, 1984, Molecular and Cellular Endocrinology.

Risk factors in children with fever and neutropenia.

P. Breitfeld, W. Rackoff, 2001, Journal of Clinical Oncology.

Influence of Hemoglobin Response to Epoetin Alfa on Quality-of-Life in Anemic Children with Cancer Receiving Myelosuppressive Chemotherapy.

Pamela S. Hinds, P. Hinds, J. Feusner, 2004 .

Identification of Molecular Predictors of Response to ZARNESTRA™ (Tipifarnib, R115777) in Relapsed and Refractory Acute Myeloid Leukemia.

David C. Atkins, Yixin Wang, Yi Zhang, 2004 .

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma.

P. Breitfeld, J. Goldman, W. Rackoff, 1994, The American journal of pediatric hematology/oncology.

Effect of erythrocytapheresis on arterial oxygen saturation and hemoglobin oxygen affinity in patients with sickle cell disease

T. Asakura, Haewon C. Kim, M. P. Reilly, 1998, American journal of hematology.